BEIGENE (06160) Zanubrutinib Sales in US and Europe Exceed Expectations; Haitong International Maintains "Outperform" Rating
Stock News
Nov 11
BEIGENE (06160) has seen stronger-than-expected sales growth of its Zanubrutinib in the US and European markets, prompting Haitong International to raise its revenue forecasts for 2025–2027 to $5.3 billion, $6.4 billion, and $7.1 billion, respectively, reflecting a compound annual growth rate of 23%. The firm also revised upward its net profit attributable to shareholders to $360 million, $660 million, and $1.05 billion for the same period, citing better-than-anticipated control over sales and R&D expenses.
Using a weighted average cost of capital (WACC) of 9% and a perpetual growth rate of 4%, Haitong International derived a target price of HK$213.1 for BEIGENE and reiterated its "Outperform" rating.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.